诺诚健华新型ADC创新药ICP-B794完成首例患者给药

Core Insights - The company, Innovent Biologics (stock code 688428), announced the completion of the first patient dosing for its self-developed targeted B7-H3 ADC innovative drug, ICP-B794 [1] Company Summary - Innovent Biologics has developed a new innovative drug, ICP-B794, which targets B7-H3 [1] - The completion of the first patient dosing marks a significant milestone in the drug's development process [1]